The expression of the HER2 receptor is a critical predictive and prognostic clinical biomarker in breast cancer, and thus we stained our TMA with an HER2 antibody to estimate HER2 expression using published criteria (54). The gene discussed is ERBB2; the disease is breast carcinoma.